Author Archives: Marta Figueiredo PhD

Mechanisms Behind Anavex 2-73’s Benefits Highlighted in Review

Activation of the sigma-1 receptor or SIGMAR1 — whose production is typically increased with age, but reduced in people with Alzheimer’s disease — drives a series of neuroprotective effects, including the clearance of unnecessary or damaged cellular components, a review study highlights. This supports the therapeutic potential of…

FDA Rejects Nuplazid to Treat Dementia-related Psychosis

The U.S. Food and Drug Administration (FDA) has rejected Acadia Pharmaceuticals’ request that Nuplazid (pimavanserin) be the first approved treatment of hallucinations and delusions associated with dementia-related psychosis. The decision comes less than nine months since the agency agreed to review the company’s supplemental new drug application, and a month…

Aduhelm Approved